China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive rights to develop, regulate, manufacture, and commercialize InventisBio’s D-1553 in mainland China. The agreement also provides Chia Tai Tianqing with potential ex-China territorial rights based on future data-sharing, although no financial details have been disclosed.
D-1553: A Promising KRAS G12C Inhibitor
D-1553 is an in-house developed KRAS G12C inhibitor by InventisBio, designed to treat non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) with KRAS G12C mutations. This innovative drug is the first KRAS G12C inhibitor to enter clinical trials in China, highlighting its potential in addressing significant unmet medical needs.
Global Clinical Trials and Phase II Progression
D-1553 has already entered various multi-center studies in the US, Australia, and South Korea, demonstrating its global potential. In China, the drug has reached the Phase II stage as a monotherapy for NSCLC patients positive for KRAS G12C, marking a significant milestone achieved in May 2022.-Fineline Info & Tech
